Loading...
XHKG
0858
Market cap15mUSD
Jun 16, Last price  
0.05HKD
1D
1.96%
1Q
15.56%
Jan 2017
-80.38%
Name

Extrawell Pharmaceutical Holdings Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-6.19%
Rev. gr., 5y
-7.91%
Revenues
59m
-18.57%
169,766,000178,265,000158,763,000165,079,000184,434,000196,291,000198,816,000157,406,000151,068,000150,673,000128,833,000142,201,000107,903,00085,762,00089,218,00077,584,00078,802,00073,925,00072,577,00059,098,000
Net income
-163m
L
-75,823,0004,187,0008,934,000-13,335,00015,551,00014,624,00011,567,00020,414,00010,876,00015,700,000565,457,00027,400,00020,796,00029,930,00064,030,00083,280,000-121,098,000130,588,000129,265,000-162,949,000
CFO
-4m
L
25,588,00016,753,00026,108,0004,349,0002,201,00031,365,00018,673,0009,476,00010,414,00082,330,000-23,487,0006,274,0005,482,000-4,883,000-15,089,000-10,258,000-232,000-1,599,0003,214,000-3,689,000
Dividend
Dec 16, 19990.0526 HKD/sh

Profile

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.
URL
http://www.extrawell.com.hk
IPO date
Mar 10, 1999
Employees
180
Domiciled in
HK
Incorporated in
BM

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
59,098
-18.57%
72,577
-1.82%
Cost of revenue
65,846
84,736
Unusual Expense (Income)
NOPBT
(6,748)
(12,159)
NOPBT Margin
Operating Taxes
2,131
1,128
Tax Rate
NOPAT
(8,879)
(13,287)
Net income
(162,949)
-226.06%
129,265
-1.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
(4,888)
BB yield
6.82%
Debt
Debt current
1,375
1,316
Long-term debt
122,321
614,267
Deferred revenue
4,171
4,382
Other long-term liabilities
(98,617)
Net debt
(945,380)
(636,166)
Cash flow
Cash from operating activities
(3,689)
3,214
CAPEX
(1,202)
(6,617)
Cash from investing activities
2,036
(12,497)
Cash from financing activities
(6,503)
(2,295)
FCF
(48,909)
(1,441)
Balance
Cash
94,271
123,958
Long term investments
974,805
1,127,791
Excess cash
1,066,121
1,248,120
Stockholders' equity
526,099
572,634
Invested Capital
711,093
702,587
ROIC
ROCE
EV
Common stock shares outstanding
2,390,000
3,290,000
Price
0.03
-55.22%
0.07
-22.99%
Market cap
71,700
-67.47%
220,430
-22.99%
EV
(812,982)
(415,888)
EBITDA
2,297
(3,494)
EV/EBITDA
119.03
Interest
18,801
15,636
Interest/NOPBT